Trial · NCT04860518

Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19

NCT04860518, Phase 2, Terminated, Faron Pharmaceuticals Ltd; results first posted 2022-10-14

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19. Trials, record NCT04860518. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04860518

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19
NCT number: NCT04860518
Status: Terminated
Phases: Phase 2
Enrollment: 7 participants, actual
Lead sponsor: Faron Pharmaceuticals Ltd
Conditions: Covid19
Interventions: IFN beta-1a, Dexamethasone
First posted: 2021-04-27
Last updated: 2023-07-21
Results first posted: 2022-10-14
Limitations and caveats: No formal statistical hypotheses were analysed due the early termination of the study with only 5 dosed subjects.

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Clinical Status at Day 14 (First Day of Study Drug is Day 1) as Measured by WHO 9-point Ordinal Scale	Day 14	WHO 9-point ordinal scale: 0 - No detectable infection 1. \- Not hospitalized, no limitations on activities 2. \- Not hospitalized, limitation on activities 3. \- Hospitalized, not requiring supplemental oxygen 4. \- Hospitalized, requiring supplemental oxygen 5. \- Hospitalized, on non-invasive ventilation or high flow oxygen devices 6. \- Hospitalized, on invasive mechanical ventilation 7. \- Hospitalized, on mechanical ventilation plus additional organ support: renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO) 8. \- Death
Secondary	In-hospital Mortality at Day 28 and Day 90	Day 28 and Day 90	Percentage of participants per study group that die when in still hospital at Day 28 or Day 90 of the trial
Secondary	Overall (All-cause) Mortality at Day 28 and Day 90	Day 28 and Day 90	Percentage of participants per study group that die within 28 days or 90 days from starting the study

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Clinical Status at Day 14 (First Day of Study Drug is Day 1) as Measured by WHO 9-point Ordinal Scale	Day 14	Only 4 patients had analyzable data on D14	units on a scale	MEAN
SECONDARY	In-hospital Mortality at Day 28 and Day 90	Day 28 and Day 90		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Overall (All-cause) Mortality at Day 28 and Day 90	Day 28 and Day 90		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Clinical Status at Day 14 (First Day of Study Drug is Day 1) as Measured by WHO 9-point Ordinal Scale	IV IFN Beta-1a	2	Standard Deviation 0	units on a scale
Clinical Status at Day 14 (First Day of Study Drug is Day 1) as Measured by WHO 9-point Ordinal Scale	IV Dexamethasone	2	Standard Deviation 0	units on a scale
In-hospital Mortality at Day 28 and Day 90	IV IFN Beta-1a	0		Participants
In-hospital Mortality at Day 28 and Day 90	IV Dexamethasone	0		Participants
Overall (All-cause) Mortality at Day 28 and Day 90	IV IFN Beta-1a	0		Participants
Overall (All-cause) Mortality at Day 28 and Day 90	IV Dexamethasone	0		Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	IV IFN Beta-1a	3
Overall Study	STARTED	IV Dexamethasone	4
Overall Study	COMPLETED	IV IFN Beta-1a	2
Overall Study	COMPLETED	IV Dexamethasone	3
Overall Study	NOT COMPLETED	IV IFN Beta-1a	1
Overall Study	NOT COMPLETED	IV Dexamethasone	1

Source ClinicalTrials.gov

Adverse events16

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Hyperglycemia	Metabolism and nutrition disorders	IV IFN Beta-1a	1	2	1
other	Hyperglycemia	Metabolism and nutrition disorders	IV Dexamethasone	0	3	0
other	Hypokalemia	Metabolism and nutrition disorders	IV IFN Beta-1a	1	2	1
other	Hypokalemia	Metabolism and nutrition disorders	IV Dexamethasone	0	3	0
other	Hypnoatremia	Metabolism and nutrition disorders	IV IFN Beta-1a	1	2	1
other	Hypnoatremia	Metabolism and nutrition disorders	IV Dexamethasone	0	3	0
other	Subdural hematoma	Injury, poisoning and procedural complications	IV IFN Beta-1a	0	2	0
other	Subdural hematoma	Injury, poisoning and procedural complications	IV Dexamethasone	1	3	1
other	Seizure	Nervous system disorders	IV IFN Beta-1a	0	2	0
other	Seizure	Nervous system disorders	IV Dexamethasone	1	3	1

1 to 10 of 16Source ClinicalTrials.gov

See all 16 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	IV IFN Beta-1a	0	2
Total, all-cause mortality	IV Dexamethasone	0	3
Total, other adverse events	IV IFN Beta-1a	1	2
Total, other adverse events	IV Dexamethasone	2	3
Total, serious adverse events	IV IFN Beta-1a	0	2
Total, serious adverse events	IV Dexamethasone	2	3

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons4

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
IV IFN Beta-1a vs IV Dexamethasone: In-hospital Mortality at Day 28 and Day 90	Trial comparisons
IV IFN Beta-1a vs IV Dexamethasone: Overall (All-cause) Mortality at Day 28 and Day 90	Trial comparisons
IV IFN Beta-1a vs IV Dexamethasone: deaths from any cause	Trial comparisons
IV IFN Beta-1a vs IV Dexamethasone: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04860518

GET https://conductscience.org/api/trials/v1/NCT04860518/registered

API reference For AI assistants